Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

被引：89
|
作者：
Fioretto, Paola [1 ]
Stefansson, Bergur V. [2 ]
Johnsson, Eva [2 ]
Cain, Valerie A. [3 ]
Sjostrom, C. David [2 ]
机构：
[1] Univ Padua, Dept Med, Clin Med 3, Via Giustiniani 2, I-35128 Padua, Italy
[2] AstraZeneca, Molndal, Sweden
[3] AstraZeneca, Wilmington, DE USA
来源：
DIABETOLOGIA | 2016年 / 59卷 / 09期
关键词：
Albuminuria; Dapagliflozin; Renal impairment; SGLT2; inhibition; Type; 2; diabetes; BLOOD-PRESSURE;
D O I：
10.1007/s00125-016-4017-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2036 / 2039
页数：4
相关论文
共 50 条
  • [41] Urinary Angiopoietin-2 Is Associated with Albuminuria in Patients with Type 2 Diabetes Mellitus
    Chen, Shan
    Li, Huiqing
    Zhang, Chun
    Li, Zhenqiong
    Wang, Qiuyuan
    Guo, Jinting
    Luo, Changqing
    Wang, Yumei
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [42] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A286 - A286
  • [43] Remogliflozin (SGLT2 Inhibitor) Significantly Reduces Albuminuria and Delays the Progression of Nephropathy in Type 2 Diabetes Mellitus Patients
    Gupta, Vishal K.
    [J]. DIABETES, 2020, 69
  • [44] Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
    Nguyen, John T.
    Molony, Donald A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (02) : JC5 - JC5
  • [45] Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients
    Qin, Yuejuan
    Baskoy, Gozde
    Triplitt, Curtis L.
    Solis-Herrera, Carolina
    Adams, John M., III
    Defronzo, Ralph A.
    Cersosimo, Eugenio
    [J]. DIABETES, 2023, 72
  • [46] Dapagliflozin does not impact renal function in patients with type 2 diabetes
    Ptaszynska, A.
    Chalamandaris, A. -G.
    Sugg, J.
    Johnsson, K.
    Parikh, S.
    List, J. F.
    [J]. DIABETOLOGIA, 2012, 55 : S107 - S107
  • [47] Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
    Hinnen, Deborah
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (03) : 92 - 102
  • [48] Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients
    Baskoy, Gozde
    Qin, Yuejuan
    Cersosimo, Eugenio
    Solis-Herrera, Carolina
    Adams, John M., III
    Defronzo, Ralph A.
    Triplitt, Curtis L.
    [J]. DIABETES, 2023, 72
  • [49] Determinants of albuminuria in people with Type 2 diabetes mellitus
    Pijls, LTJ
    de Vries, H
    Kriegsman, DMW
    Donker, AJM
    van Eijk, JT
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 52 (02) : 133 - 143
  • [50] Efficacy and Safety of Dapagliflozin as Monotherapy for Type 2 Diabetes Mellitus in Japanese Patients
    Kaku, Kohei
    Inoue, Satoshi
    Matsuoka, Osamu
    Kiyosue, Arihiro
    Azuma, Haruna
    Hayashi, Nobuya
    Tokudome, Takuto
    Langkilde, Anna Maria
    Parikh, Shamik
    [J]. DIABETES, 2012, 61 : A260 - A260
12345